IGM Biosciences News

IGM Biosciences Inc (IGMS) Q1 2024 Earnings: Aligns With EPS Projections Amidst Clinical ...

Yahoo Finance02:38

Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.

Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.

Zhitong FinanceMay 9 20:50

Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target

Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.

BenzingaMay 9 20:49

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)

TipRanksMay 9 20:20

RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk

IGM Biosciences (IGMS) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $12 to $48.

MT NewswiresMay 9 19:38

IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p

BenzingaMay 9 06:10

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

Yahoo FinanceMay 9 05:55

Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000

04:42 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000

MT NewswiresMay 9 04:42

IGM Biosciences | 10-Q: Quarterly report

Futu NewsMay 9 04:11 · Announcements

Press Release: IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update - Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment com

Dow JonesMay 9 04:10

IGM Biosciences 1Q Loss $49.8M >IGMS

IGM Biosciences 1Q Loss $49.8M >IGMS

Dow JonesMay 9 04:10

IGM Biosciences 1Q Loss/Shr 83c >IGMS

IGM Biosciences 1Q Loss/Shr 83c >IGMS

Dow JonesMay 9 04:10

IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management

GlobeNewswireMay 7 19:00

Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)

TipRanksApr 19 02:25

IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow JonesApr 18 18:43

HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences with a Neutral and maintains $12 price target.

Analyst UpgradesApr 18 18:33

Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)

TipRanksApr 18 18:30

Why IGM Biosciences Is Rising In Pre-market?

RTTNewsApr 17 21:24

IGM Biosciences Announces Worldwide Collaboration Agreement With Sanofi To Create And Develop IgM Agonist Antibodies Will Focus Exclusively On Immunology/Inflammation Targets

IGM Biosciences Announces Worldwide Collaboration Agreement With Sanofi To Create And Develop IgM Agonist Antibodies Will Focus Exclusively On Immunology/Inflammation Targets

BenzingaApr 17 20:33

IGM Biosciences Announces Refocusing of Sanofi Collaboration

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the

GlobeNewswireApr 17 20:30